[HTML][HTML] Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of …

…, M Decobert, A Cudennec, C Voltz, D Boulay… - …, 2005 - nature.com
… -controlled, have shown that d-cycloserine, glycine, and d-serine improve some aspects of
D-Cycloserine, glycine, and d-serine are compounds that act as agonists at the glycine B …

Endogenous ADAR-mediated RNA editing in non-human primates using stereopure chemically modified oligonucleotides

P Monian, C Shivalila, G Lu, M Shimizu, D Boulay… - Nature …, 2022 - nature.com
… 1 injections once daily for 5 d. We evaluated liver biopsies for editing 2 d and 45 d postdose
(one monkey was evaluated 38 d postdose). At 2 d postdose, AIMers directed efficient ACTB …

Serologic testing of US blood donations to identify severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–reactive antibodies: December 2019–January …

…, M Ategbole, S Bolcen, D Boulay… - Clinical Infectious …, 2021 - academic.oup.com
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that
causes coronavirus disease 2019 (COVID-19), was first identified in Wuhan, China, in …

Serologic testing of US blood donations to identify SARS-CoV-2-reactive antibodies: December 2019-January 2020

…, B Alston, M Ategbole, S Bolcen, D Boulay… - … Diseases: An Official …, 2020 - ncbi.nlm.nih.gov
Background SARS-CoV-2, the virus that causes COVID-19 disease, was first identified in
Wuhan, China in December 2019, with subsequent worldwide spread. The first US cases were …

[HTML][HTML] The selective GSK3 inhibitor, SAR502250, displays neuroprotective activity and attenuates behavioral impairments in models of neuropsychiatric symptoms of …

G Griebel, J Stemmelin, M Lopez-Grancha, D Boulay… - Scientific reports, 2019 - nature.com
… on (A), locomotor activity prior to the exposure to the threat; (B), flight response in response
to the approaching rat; (C), risk assessment when the rat was chasing the mouse, and (D), …

Impact of guanidine-containing backbone linkages on stereopure antisense oligonucleotides in the CNS

…, S Akare, R Alam, A Andreucci, D Boulay… - Nucleic acids …, 2022 - academic.oup.com
Attaining sufficient tissue exposure at the site of action to achieve the desired pharmacodynamic
effect on a target is an important determinant for any drug discovery program, and this …

Accumulated body burden and endogenous release of lead in employees of a lead smelter.

DE Fleming, D Boulay, NS Richard… - Environmental …, 1997 - ehp.niehs.nih.gov
Bone lead levels for 367 active and 14 retired lead smelter workers were measured in vivo by
X-ray fluorescence in May-June 1994. The bone sites of study were the tibia and calcaneus…

Dopamine D2 receptor knock-out mice are insensitive to the hypolocomotor and hypothermic effects of dopamine D2/D3 receptor agonists

D Boulay, R Depoortere, G Perrault, E Borrelli… - …, 1999 - Elsevier
… DA D 2 receptor is the subtype that mediates hypothermia and hypolocomotion produced
by DA D 2 /D 3 receptor agonists, we tested the effects of ip administration of the DA D 2 /D 3 …

Characterization of SSR103800, a selective inhibitor of the glycine transporter-1 in models predictive of therapeutic activity in schizophrenia

D Boulay, P Pichat, G Dargazanli… - Pharmacology …, 2008 - Elsevier
… Another, though more indirect argument for this hypo-NMDA hypothesis, is based on the
observation that compounds such as d-cycloserine, glycine, alanine and d-serine, which …

Dopamine D3 receptor agonists produce similar decreases in body temperature and locomotor activity in D3 knock-out and wild-type mice

D Boulay, R Depoortere, W Rostene, G Perrault… - …, 1999 - Elsevier
… ) at the D 3 than the D 2 subtype. In order to investigate further the role of D 3 receptors in …
three DA receptor agonists reported to be selective for the D 3 receptor subtype (7-OH-DPAT…